David Thomas, DO
Payments from drug & device makers
Across 116 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$374
- SK Life Science, Inc.$276
- AbbVie$247
- Teva Pharmaceuticals USA, Inc.$216
- Biogen$203
- Novartis$159
- plus $603 from 11 others
What the payments were for
- Food & beverage$1,92893%
- Education$1497%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 32 | $374 |
| SK Life Science, Inc. | 12 | $276 |
| AbbVie | 14 | $247 |
| Teva Pharmaceuticals USA, Inc. | 3 | $216 |
| Biogen | 9 | $203 |
| Novartis | 16 | $159 |
| Supernus Pharmaceuticals, Inc. | 15 | $155 |
| Harmony Biosciences LLC | 3 | $118 |
| Neuronetics, Inc. | 2 | $89 |
| UCB, Inc. | 2 | $54 |
| Eisai Inc. | 2 | $45 |
| Axsome Therapeutics, Inc. | 1 | $40 |
| AstraZeneca | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$112
How this compares
$2,077 in reported general payments places this provider in the 55th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Glatiramer Acetate | 17 | $27,217 |
| Lacosamide | 51 | $11,655 |
| Rasagiline Mesylate | 11 | $6,015 |
| Rivastigmine | 22 | $4,758 |
| Carbamazepine ErCarbamazepine | 34 | $3,711 |
| Pregabalin | 56 | $2,723 |
| Memantine Hcl | 82 | $2,457 |
| Donepezil Hcl | 124 | $2,205 |
| Memantine Hcl ErMemantine Hcl | 21 | $1,930 |
| Levetiracetam | 41 | $1,813 |
| Gabapentin | 105 | $1,710 |
| Carbamazepine | 24 | $1,684 |
| Divalproex Sodium | 28 | $983 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 32 | $905 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 27 | $831 |
Paid to pharmacies, not to this prescriber.
Other neurology in Media
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.